These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15984413)

  • 1. Histological evaluation for "bone quality" on two mouse models with different bone remodeling.
    Amizuka N; Shimomura J; Li M; Nasu M; Maeda T
    J Bone Miner Metab; 2005; 23 Suppl():43-7. PubMed ID: 15984413
    [No Abstract]   [Full Text] [Related]  

  • 2. Bone remodelling: a signalling system for osteoclast regulation.
    Filvaroff E; Derynck R
    Curr Biol; 1998 Sep; 8(19):R679-82. PubMed ID: 9768352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism.
    Hofbauer LC
    Eur J Endocrinol; 1999 Sep; 141(3):195-210. PubMed ID: 10474114
    [No Abstract]   [Full Text] [Related]  

  • 4. Osteoprotegrin knockout mice demonstrate abnormal remodeling of the otic capsule and progressive hearing loss.
    Zehnder AF; Kristiansen AG; Adams JC; Kujawa SG; Merchant SN; McKenna MJ
    Laryngoscope; 2006 Feb; 116(2):201-6. PubMed ID: 16467704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteopetrosis and osteoporosis: two sides of the same coin.
    Lazner F; Gowen M; Pavasovic D; Kola I
    Hum Mol Genet; 1999; 8(10):1839-46. PubMed ID: 10469835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism].
    Stajszczyk M
    Pol Arch Med Wewn; 2002 Sep; 108(3):915-24. PubMed ID: 12600190
    [No Abstract]   [Full Text] [Related]  

  • 7. Osteoprotegerin: a link between osteoporosis and arterial calcification?
    Hofbauer LC; Schoppet M
    Lancet; 2001 Jul; 358(9278):257-9. PubMed ID: 11498208
    [No Abstract]   [Full Text] [Related]  

  • 8. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice.
    Clohisy DR; Ramnaraine ML; Scully S; Qi M; Van G; Tan HL; Lacey DL
    J Orthop Res; 2000 Nov; 18(6):967-76. PubMed ID: 11192258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
    Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
    Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoclast induction in periodontal tissue during experimental movement of incisors in osteoprotegerin-deficient mice.
    Oshiro T; Shiotani A; Shibasaki Y; Sasaki T
    Anat Rec; 2002 Apr; 266(4):218-25. PubMed ID: 11920384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
    Bucay N; Sarosi I; Dunstan CR; Morony S; Tarpley J; Capparelli C; Scully S; Tan HL; Xu W; Lacey DL; Boyle WJ; Simonet WS
    Genes Dev; 1998 May; 12(9):1260-8. PubMed ID: 9573043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent advances in the regulation of bone remodeling].
    Matsumoto T
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():37-46. PubMed ID: 15035093
    [No Abstract]   [Full Text] [Related]  

  • 13. Bone morphogenetic protein-induced heterotopic bone in osteopetrosis.
    Miyazawa K; Kawai T; Urist MR
    Clin Orthop Relat Res; 1996 Mar; (324):259-68. PubMed ID: 8595766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass.
    Li CY; Jepsen KJ; Majeska RJ; Zhang J; Ni R; Gelb BD; Schaffler MB
    J Bone Miner Res; 2006 Jun; 21(6):865-75. PubMed ID: 16753017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of altered bone remodeling and retention of cement lines on bone quality in osteopetrotic aged c-Src-deficient mice.
    Nakayama H; Takakuda K; Matsumoto HN; Miyata A; Baba O; Tabata MJ; Ushiki T; Oda T; McKee MD; Takano Y
    Calcif Tissue Int; 2010 Feb; 86(2):172-83. PubMed ID: 20063091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double mutations in klotho and osteoprotegerin gene loci rescued osteopetrotic phenotype.
    Yamashita T; Okada S; Higashio K; Nabeshima Y; Noda M
    Endocrinology; 2002 Dec; 143(12):4711-7. PubMed ID: 12446599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defective bone remodelling in osteoprotegerin-deficient mice.
    Amizuka N; Shimomura J; Li M; Seki Y; Oda K; Henderson JE; Mizuno A; Ozawa H; Maeda T
    J Electron Microsc (Tokyo); 2003; 52(6):503-13. PubMed ID: 14756238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha.
    Hayashi S; Yamada T; Tsuneto M; Yamane T; Takahashi M; Shultz LD; Yamazaki H
    J Immunol; 2003 Nov; 171(10):5130-9. PubMed ID: 14607912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.
    Min H; Morony S; Sarosi I; Dunstan CR; Capparelli C; Scully S; Van G; Kaufman S; Kostenuik PJ; Lacey DL; Boyle WJ; Simonet WS
    J Exp Med; 2000 Aug; 192(4):463-74. PubMed ID: 10952716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pitting phosphate transport inhibitors against vascular calcification.
    Demer LL; Tintut Y
    Circ Res; 2006 Apr; 98(7):857-9. PubMed ID: 16614308
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.